European Medicines Agency starts rolling review of Celltrion antibody regdanvimab for COVID-19

The decision to start the rolling review is based on preliminary results from an ongoing study looking at the ability of regdanvimab to treat COVID-19. The rolling review will continue until enough evidence is available to support a formal marketing authorisation application.

Source:

European Medicines Agency